<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1 Healing of Erosive Esophagitis<BR>                     <BR>                        Two multi-center, double-blind, active-controlled, randomized, 8-week studies were conducted in patients with endoscopically confirmed EE. Severity of the disease was classified based on the Los Angeles Classification Grading System (Grades A-D). Patients were randomized to one of the following three treatment groups: DEXILANT 60 mg daily, DEXILANT 90 mg daily or lansoprazole 30 mg daily. Patients who were H. pylori positive or who had Barrett's Esophagus and/or definite dysplastic changes at baseline were excluded from these studies. A total of 4092 patients were enrolled and ranged in age from 18 to 90 years (median age 48 years) with 54% male. Race was distributed as follows: 87% Caucasian, 5% Black and 8% other. Based on the Los Angeles Classification, 71% of patients had mild EE (Grades A and B) and 29% of patients had moderate to severe EE (Grades C and D) before treatment.<BR>                        The studies were designed to test non-inferiority. If non-inferiority was demonstrated then superiority would be tested. Although non-inferiority was demonstrated in both studies, the finding of superiority in one study was not replicated in the other.<BR>                        The proportion of patients with healed EE at week 4 or 8 is presented below in Table 5. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="table5"><BR>                           <caption ID="id_7ab00bb0-233d-44da-bf6b-45e3b89ca56d">Table 5: EE Healing Rates: All Grades</caption><BR>                           <col width="8%" align="center"/><BR>                           <col width="15%" align="center"/><BR>                           <col width="25%" align="center"/><BR>                           <col width="15%" align="center"/><BR>                           <col width="15%" align="center"/><BR>                           <col width="22%" align="center"/><BR>                           <thead><BR>                              <tr ID="id_32b20682-b50f-4d7c-9439-38f610bdd508" styleCode="Botrule"><BR>                                 <td align="left" valign="bottom" styleCode="Lrule Rrule">Study</td><BR>                                 <td align="left" valign="bottom" styleCode="Rrule">Number of Patients<br/>(N)<BR>                                 </td><BR>                                 <td align="left" valign="bottom" styleCode="Rrule">Treatment Group<br/>(daily)</td><BR>                                 <td align="left" valign="bottom" styleCode="Rrule">Week 4<br/>% Healed</td><BR>                                 <td align="left" valign="bottom" styleCode="Rrule">Week 8<BR>                                    <br/>% Healed</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">(95% CI) for the Treatment Difference (DEXILANT&#8211; Lansoprazole) by Week 8 </td><BR>                              </tr><BR>                           </thead><BR>                           <tfoot ID="id_7e481dff-32a6-42e2-848e-4a67b78f6900"><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="6" styleCode="Lrule Rrule">CI = Confidence interval</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr ID="id_639cff76-49f4-43f4-aa2c-85ea6db1d2b4" styleCode="Toprule"><BR>                                 <td align="left" valign="top" rowspan="2" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">1</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Rrule">657</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">DEXILANT 60 mg</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">70</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">87</td><BR>                                 <td align="left" valign="top" rowspan="2" styleCode="Rrule">(-1.5, 6.1)<footnote ID="t5f1">Demonstrated non-inferiority to lansoprazole</footnote><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_22ef0584-1eab-4c85-b2bc-a7e28a0c3444"><BR>                                 <td align="left" valign="top" styleCode="Lrule Rrule">648</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">Lansoprazole 30 mg</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">65</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">85</td><BR>                              </tr><BR>                              <tr ID="id_a7fe8e18-bfbe-4892-b0eb-05af339a0b5d"><BR>                                 <td align="left" valign="top" rowspan="2" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">2</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Rrule">639</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">DEXILANT 60 mg</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">66</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">85</td><BR>                                 <td align="left" valign="top" rowspan="2" styleCode="Rrule">(2.2, 10.5)<footnoteRef IDREF="t5f1"/><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_5ad03dfe-e9df-492d-838b-268cd7d3bc0e"><BR>                                 <td align="left" valign="top" styleCode="Lrule Rrule">656</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">Lansoprazole 30 mg</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">65</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">79</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>DEXILANT 90 mg was studied and did not provide additional clinical benefit over DEXILANT 60 mg.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2 Maintenance of Healed Erosive Esophagitis<BR>                     <BR>                        A multi-center, double-blind, placebo-controlled, randomized study was conducted in patients who successfully completed an EE study and showed endoscopically confirmed healed EE. Maintenance of healing and symptom resolution over a six-month period were evaluated with DEXILANT 30 mg or 60 mg once daily compared to placebo. A total of 445 patients were enrolled and ranged in age from 18 to 85 years (median age 49 years), with 52% female. Race was distributed as follows: 90% Caucasian, 5% Black and 5% other.<BR>                         Sixty-six percent of patients treated with 30 mg of DEXILANT remained healed over the six-month time period as confirmed by endoscopy (see Table 6). <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="table6"><BR>                           <caption ID="id_c712b5ab-3c22-4da6-a3a4-9cdd61c3f705">Table 6: Maintenance Rates of Healed EE at Month 6</caption><BR>                           <col width="34%" align="center"/><BR>                           <col width="33%" align="center"/><BR>                           <col width="33%" align="center"/><BR>                           <thead><BR>                              <tr ID="id_a32d9732-b441-43c1-b833-25320e899ca1" styleCode="Botrule"><BR>                                 <td align="left" valign="top" styleCode="Rrule">Number of Patients <br/> (N)<BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Rrule">Treatment Group <br/> (daily) </td><BR>                                 <td align="left" valign="top"> Maintenance Rate <br/> (%) </td><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr ID="id_62d9ab08-9d1b-4a96-a4f8-3e9a043372f5" styleCode="Toprule"><BR>                                 <td align="left" valign="top" styleCode="Rrule">125</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">DEXILANT 30 mg</td><BR>                                 <td align="left" valign="top">66.4<BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_bf6a39a0-043f-4cae-8ffb-8fcc0c404a7a" styleCode="Botrule"><BR>                                 <td align="left" valign="top" styleCode="Rrule">119</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">Placebo</td><BR>                                 <td align="left" valign="top">14.3</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>DEXILANT 60 mg was studied and did not provide additional clinical benefit over DEXILANT 30 mg. <BR>                        The effect of DEXILANT 30 mg on maintenance of relief of heartburn was also evaluated. Upon entry into the maintenance study, a majority of patients' baseline heartburn severity was rated as none. DEXILANT 30 mg demonstrated a statistically significantly higher percent of 24-hour heartburn-free periods compared to placebo over the 6-month treatment period (see Table 7). The majority of patients treated with placebo discontinued due to relapse of EE between month two and month six.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="tbl7"><BR>                           <caption ID="id_b5183a75-2a3d-4154-9ede-21ea0242e3d3">Table 7: Median Percentage of 24-Hour Heartburn-Free Periods of the Maintenance of Healed EE Study</caption><BR>                           <col width="15%" align="center"/><BR>                           <col width="14%" align="center"/><BR>                           <col width="14%" align="center"/><BR>                           <col width="14%" align="center"/><BR>                           <col width="14%" align="center"/><BR>                           <col width="14%" align="center"/><BR>                           <col width="15%" align="center"/><BR>                           <thead><BR>                              <tr ID="id_d4f21b38-3b6c-42f9-a06c-0379396e2d3a" styleCode="Toprule"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule">Overall Treatment<BR>                                 </td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule">Month 1</td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Lrule Botrule Rrule">Month 6</td><BR>                              </tr><BR>                              <tr ID="id_53f62d9f-8bd6-4688-bb75-3b10da5002e7" styleCode="Botrule"><BR>                                 <td align="left" valign="top" styleCode="Lrule Rrule">Treatment Group <br/>(daily)</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">N</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">Heartburn-Free 24-hour Periods <br/>(%)</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">N</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">Heartburn-Free 24-hour Periods <br/>(%)</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">N</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">Heartburn-Free 24-hour Periods <br/> (%)</td><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr ID="id_0203884a-01bf-4f11-b408-b546e419477e" styleCode="Toprule"><BR>                                 <td align="left" valign="top" styleCode="Lrule Rrule">DEXILANT 30 mg</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">132</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">96.1 <BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Rrule">126</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">96.7</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">80</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">98.3</td><BR>                              </tr><BR>                              <tr ID="id_741df859-5ca9-49b0-95dc-d82241701505" styleCode="Botrule"><BR>                                 <td align="left" valign="top" styleCode="Lrule Rrule">Placebo</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">141</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">28.6</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">117</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">28.6</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">23</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">73.3</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.3 Symptomatic Non-Erosive GERD<BR>                     <BR>                        A multi-center, double-blind, placebo-controlled, randomized, 4-week study was conducted in patients with a diagnosis of symptomatic non-erosive GERD made primarily by presentation of symptoms. These patients who identified heartburn as their primary symptom, had a history of heartburn for 6 months or longer, had heartburn on at least 4 of 7 days immediately prior to randomization and had no esophageal erosions as confirmed by endoscopy. However, patients with symptoms which were not acid-related may not have been excluded using these inclusion criteria. Patients were randomized to one of the following treatment groups: DEXILANT 30 mg daily, 60 mg daily, or placebo. A total of 947 patients were enrolled and ranged in age from 18 to 86 years (median age 48 years) with 71% female. Race was distributed as follows: 82% Caucasian, 14% Black and 4% other.<BR>                        DEXILANT 30 mg provided statistically significantly greater percent of days with heartburn-free 24-hour periods over placebo as assessed by daily diary over 4 weeks (see Table 8). DEXILANT 60 mg was studied and provided no additional clinical benefit over DEXILANT 30 mg.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="tble8"><BR>                           <caption ID="id_c08d695a-c27b-4604-9357-15d267457d8c">Table 8: Median Percentages of 24-Hour Heartburn-Free Periods During the 4 Week Treatment Period of the Symptomatic Non-Erosive GERD Study</caption><BR>                           <col width="34%" align="center"/><BR>                           <col width="33%" align="center"/><BR>                           <col width="33%" align="center"/><BR>                           <thead><BR>                              <tr ID="id_c1f4328c-eea9-4913-99ff-d064888a59d3" styleCode="Botrule"><BR>                                 <td align="left" valign="top" styleCode="Rrule"> N </td><BR>                                 <td align="left" valign="top" styleCode="Rrule"> Treatment Group <br/> (daily) </td><BR>                                 <td align="left" valign="top"> Heartburn-Free <br/> 24-hour Periods <br/> (%) </td><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr ID="id_2d32aa6f-a199-4fe2-8935-9900c8835a79" styleCode="Toprule"><BR>                                 <td align="left" valign="top" styleCode="Rrule">312</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">DEXILANT 30 mg</td><BR>                                 <td align="left" valign="top">54.9<BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_cbb531bd-e323-4d5a-a927-18e31f55a910" styleCode="Botrule"><BR>                                 <td align="left" valign="top" styleCode="Rrule">310</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">Placebo</td><BR>                                 <td align="left" valign="top">18.5</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>A higher percentage of patients on DEXILANT 30 mg had heartburn-free 24-hour periods compared to placebo as early as the first three days of treatment and this was sustained throughout the treatment period (percentage of patients on Day 3: DEXILANT 38% versus placebo 15%; on Day 28: DEXILANT 63% versus placebo 40%).<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>